Forbes Earnings Preview: Boston Scientific By Narrative Science 0 comments, 0 called-out + Comment now + Comment now
Wall Street is expecting lower profit for Boston Scientific (BSX) when the company reports its fourth quarter results on Thursday, February 2, 2012. Analysts are expecting earnings per share of 8 cents after the company booked a profit of 20 cents a share a year earlier.
What to Expect:
The consensus estimate hasn’t changed over the past month, but it’s down from three months ago when it was 9 cents. Analysts are projecting earnings of 44 cents per share for the fiscal year.
Analysts project revenue to fall 4.6% year-over-year to $1.91 billion for the quarter, after being $2 billion a year ago. For the year, revenue is expected to come in at $7.68 billion.
Trends to Watch For:
Over the last four quarters, the company saw a year-over-year drop in revenue by an average of 1.3%. The biggest fall was in the fourth quarter of the last fiscal year, when it fell 3.7% from the year-earlier quarter.
Analysts generally think investors should stand pat on Boston Scientific, with 18 of 26 analysts rating it hold. Analyst sentiment has waned during the last three months.
Boston Scientific is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. One of Boston Scientific’s main competitors in the healthcare equipment and supplies industry, Medtronic (MDT), will report earnings on February 21, 2012. Other competitors in the healthcare sector include: St. Jude Medical (STJ), Merit Medical Systems (MMSI), and C.R. Bard (BCR).
Recent Price Movement:
The stock price has increased from $5.58 on November 1, 2011 to $5.93 over the past quarter.